Literature DB >> 11950549

Precipitation and determination of the onset and course of schizophrenia by substance abuse--a retrospective and prospective study of 232 population-based first illness episodes.

Babette Bühler1, Martin Hambrecht, Walter Löffler, Wolfram an der Heiden, Heinz Häfner.   

Abstract

Onset and lifetime prevalence of substance abuse were assessed retrospectively using the IRAOS interview in a population-based, controlled sample of 232 first episodes of schizophrenia (ABC sample). Subjects with schizophrenia were twice as likely as controls to have a lifetime history of substance abuse at the age of first admission (alcohol abuse: 23.7 versus 12.3%; drug abuse: 14.2 versus 7.0%). 88% of the patients with drug abuse took cannabis. The sequence of substance abuse and schizophrenia was studied on the timing of abuse onset and illness onset, the latter as based on various definitions: first sign of the disorder, first psychotic symptom and first admission. 62% of the patients with drug abuse and 51% of those with alcohol abuse began the habit before illness onset (=first sign of the disorder). Abuse onset and illness onset occurred highly significantly within the same month (drug abuse in 34.6%, alcohol abuse in 18.2%). Unexpectedly, no temporal correlation was found between abuse onset and the onset of the first psychotic episode. We concluded that a small proportion of schizophrenias might have been precipitated by substance--mainly cannabis--abuse. Long-term effects of early substance abuse were studied prospectively at six cross-sections over five years from first admission on in a subsample of 115 first episodes of schizophrenia. Abusers showed significantly more positive symptoms and a decrease in affective flattening compared with controls. Five-year outcome as based on treatment compliance, utilization of rehabilitative measures and rate of employment was also poorer for patients with than without early substance abuse.

Entities:  

Mesh:

Year:  2002        PMID: 11950549     DOI: 10.1016/s0920-9964(01)00249-3

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  29 in total

1.  Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.

Authors:  Serge Sevy; Delbert G Robinson; Suzanne Sunday; Barbara Napolitano; Rachel Miller; Joanne McCormack; John Kane
Journal:  Psychiatry Res       Date:  2011-06-01       Impact factor: 3.222

Review 2.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

3.  Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.

Authors:  Serge Sevy; Delbert G Robinson; Barbara Napolitano; Raman C Patel; Handan Gunduz-Bruce; Rachel Miller; Joanne McCormack; Beth S Lorell; John Kane
Journal:  Schizophr Res       Date:  2010-05-14       Impact factor: 4.939

Review 4.  Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment.

Authors:  Jennifer P Wisdom; Jennifer I Manuel; Robert E Drake
Journal:  Psychiatr Serv       Date:  2011-09       Impact factor: 3.084

5.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

6.  Depression in the long-term course of schizophrenia.

Authors:  Wolfram an der Heiden; Regina Könnecke; Kurt Maurer; Daniel Ropeter; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 7.  The Epidemiology and Associated Phenomenology of Formal Thought Disorder: A Systematic Review.

Authors:  Eric Roche; Lisa Creed; Donagh MacMahon; Daria Brennan; Mary Clarke
Journal:  Schizophr Bull       Date:  2014-09-01       Impact factor: 9.306

8.  Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders.

Authors:  Mary E Kelley; Claire Ramsay Wan; Beth Broussard; Anthony Crisafio; Sarah Cristofaro; Stephanie Johnson; Thomas A Reed; Patrick Amar; Nadine J Kaslow; Elaine F Walker; Michael T Compton
Journal:  Schizophr Res       Date:  2016-01-17       Impact factor: 4.939

9.  A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development.

Authors:  Chaturaka Rodrigo; Srina Welgama; Alwis Gunawardana; Chinthaka Maithripala; Gamini Jayananda; Senaka Rajapakse
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-07-08

10.  A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia.

Authors:  Rachel Miller; Geoffrey Ream; Joanne McCormack; Handan Gunduz-Bruce; Serge Sevy; Delbert Robinson
Journal:  Schizophr Res       Date:  2009-05-28       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.